Table 3.
Clinical and laboratory data for the first episode of newly described patients with DGKE
| ID | Hemoglobin Nadir, g/dl | LDH, IU/L | Platelet Nadir, 103/μl | sCr Peak, mg/dl | Proteinuria | Hematuria | HTN | Triggers | Dialysis | Other Treatments | Recovery of Renal Function |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 1.1 | 5.5 | N/A | 214 | 4 | N/A | N/A | Yes | Yes (viral) | Yes | None | Yes |
| 1.2 | 6.0 | 3207 | 207 | 1.1 | Yes, NR | Yes | Yes | Unknown | No | PI | Yes |
| 2.1 | 4.7 | 1235 | 25 | 4.0 | Yes, NR | Yes | Yes | Yes (GE) | Yes | None | Yes |
| 2.2 | 6.8 | 694 | 33 | 2.33 | Yes, NR | Yes | Yes | Yes (viral) | Yes | PE, steroids | Yes |
| 3.1 | 9.6 | 496 | 649 | 0.3 | Yes, NR | Yes | Yes | Yes (viral) | No | ACEi, heparin | Yes |
| 4.1 | 5.7 | 2154 | 45 | 4.4 | Yes, NR | Yes | Yes | Yes (viral) | Yes | PI | Yes |
| 5.1 | 8.2 | 7337 | 25 | 2.2 | N/A | N/A | Yes | Yes (viral) | Yes | PE, eculizumab | Yes |
| 6.1 | 11.2 | 1843 | 135 | <0.2 | Yes, NR | Yes | Yes | Yes (viral) | Yes | Steroids, PI, PE, eculizumab | Yes |
| 7.1 | 6.1 | 11,994 | 20 | 3.8 | Yes, NR | Yes | Yes | Yes (GE) | Yes | PI | Yes |
| 8.1 | 6.0 | N/A | 60 | 1.3 | Yes, NR | N/A | Yes | Yes (GE) | No | Steroids, PE, cyclosporin A, cyclophosphamide, vincristine | Yes |
LDH, lactate dehydrogenase; sCr, serum creatinine; HTN, hypertension; N/A, not available; NR, nephrotic range; PI, plasma infusions; GE, gastroenteritis; PE, plasma exchange; ACEi, angiotensin-converting enzyme inhibitors.